- Home
- DYN vs CIM Comparison
DYN vs CIM Comparison
Compare DYN & CIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DYN
- CIM
- Stock Information
- Founded
- DYN 1984
- CIM 2007
- Country
- DYN United States
- CIM United States
- Employees
- DYN N/A
- CIM N/A
- Industry
- DYN Medicinal Chemicals and Botanical Products
- CIM Real Estate Investment Trusts
- Sector
- DYN Health Care
- CIM Real Estate
- Exchange
- DYN Nasdaq
- CIM Nasdaq
- Market Cap
- DYN 1.2B
- CIM 1.1B
- IPO Year
- DYN 2020
- CIM 2007
- Fundamental
- Price
- DYN $9.38
- CIM $14.13
- Analyst Decision
- DYN Strong Buy
- CIM Buy
- Analyst Count
- DYN 15
- CIM 3
- Target Price
- DYN $43.07
- CIM $15.50
- AVG Volume (30 Days)
- DYN 3.3M
- CIM 480.5K
- Earning Date
- DYN 08-11-2025
- CIM 08-06-2025
- Dividend Yield
- DYN N/A
- CIM 10.47%
- EPS Growth
- DYN N/A
- CIM N/A
- EPS
- DYN N/A
- CIM 1.52
- Revenue
- DYN N/A
- CIM $326,755,000.00
- Revenue This Year
- DYN N/A
- CIM $18.51
- Revenue Next Year
- DYN N/A
- CIM $3.88
- P/E Ratio
- DYN N/A
- CIM $9.30
- Revenue Growth
- DYN N/A
- CIM 11.90
- 52 Week Low
- DYN $6.36
- CIM $9.85
- 52 Week High
- DYN $47.45
- CIM $16.89
- Technical
- Relative Strength Index (RSI)
- DYN 45.89
- CIM 56.94
- Support Level
- DYN $8.95
- CIM $13.75
- Resistance Level
- DYN $9.83
- CIM $14.18
- Average True Range (ATR)
- DYN 0.55
- CIM 0.22
- MACD
- DYN 0.17
- CIM -0.04
- Stochastic Oscillator
- DYN 74.58
- CIM 55.88
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
About CIM Chimera Investment Corporation
Chimera Investment Corporation is a real estate investment trust engaged in investing in a portfolio of mortgage assets on a leveraged basis. These investments include a variety of government-sponsored agency residential mortgage-backed securities, or RMBS, non-agency RMBS, agency commercial mortgage-backed securities, residential mortgage loans, and other real estate-related securities. Agency mortgage-backed securities represent the share of this portfolio, while subprime residential mortgage loans and non-agency RMBS also make up substantial shares.